According to new data from the phase III IMpower010 trial, adjuvant atezolizumab improves overall survival compared with best supportive care for some patients with operable non–small cell lung cancer. These results build on previous study findings, in which the immune checkpoint inhibitor, given after surgery and adjuvant chemotherapy, was shown to significantly decrease the likelihood of disease progression.

You do not currently have access to this content.